α1b Tubulin Inhibitors are a specific class of chemical compounds that target and interact with the α1b isotype of tubulin, a vital protein involved in the cellular cytoskeleton. Tubulin is an essential component of microtubules, which are dynamic structures responsible for maintaining cell shape, facilitating intracellular transport, and assisting in cell division processes. These inhibitors exhibit a selective binding affinity towards the α1b isotype of tubulin, which is predominantly expressed in certain cells and tissues. The primary mode of action of α1b Tubulin Inhibitors lies in their ability to interfere with the polymerization of microtubules by binding to the α1b tubulin subunit, a process crucial for microtubule assembly. As a result, the inhibitors disrupt the dynamic stability of microtubules, leading to alterations in their organization and function within the cell.
By specifically targeting the α1b isotype, these inhibitors demonstrate a distinct mechanism compared to other tubulin-targeting agents. Due to their specific interactions with α1b tubulin, these inhibitors hold promise for potential applications in cell biology research and mechanistic studies. By perturbing microtubule dynamics in a selective manner, researchers can gain valuable insights into cellular processes that rely on microtubule function. Furthermore, the study of α1b Tubulin Inhibitors may also contribute to a better understanding of tubulin isotype diversity and its role in cellular physiology. It is important to note that, while α1b Tubulin Inhibitors show considerable potential for research purposes, further investigation is necessary to uncover their full range of effects and implications within cellular contexts. The precise biological consequences of targeting α1b tubulin remain an active area of investigation, and ongoing research may shed more light on their possible applications in various fields of science.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel is one of the most well-known α1b tubulin inhibitors. It stabilizes microtubules, preventing depolymerization and interfering with the cell division process. It is studied in the research of various cancers, including breast, ovarian, and lung cancer. | ||||||
Docetaxel | 114977-28-5 | sc-201436 sc-201436A sc-201436B | 5 mg 25 mg 250 mg | $87.00 $332.00 $1093.00 | 16 | |
Docetaxel also stabilizes microtubules, leading to cell cycle arrest and apoptosis. | ||||||
Eribulin | 253128-41-5 | sc-507547 | 5 mg | $865.00 | ||
Eribulin is a synthetic analogue of halichondrin B, a natural product found in marine sponges. It inhibits microtubule growth and leads to cell cycle arrest. Eribulin is used for metastatic breast cancer. | ||||||
Vinorelbine base | 71486-22-1 | sc-205885 sc-205885A sc-205885B sc-205885C sc-205885D | 1 mg 5 mg 25 mg 100 mg 1 g | $29.00 $81.00 $260.00 $791.00 $1977.00 | ||
Vinorelbine is a semi-synthetic vinca alkaloid that blocks mitotic spindle formation by binding to tubulin. It is studied in the research of non-small cell lung cancer and breast cancer. | ||||||
Estramustine | 2998-57-4 | sc-353281 sc-353281A | 100 mg 1 g | $265.00 $743.00 | ||
Estramustine is a combination of estrogen and a nitrogen mustard derivative. It inhibits microtubule formation and has been studied in the research of advanced prostate cancer. | ||||||
ABT 751 | 141430-65-1 | sc-361097 sc-361097A | 10 mg 50 mg | $179.00 $825.00 | ||
ABT-751 is a synthetic tubulin-binding agent that inhibits microtubule assembly, leading to cell cycle arrest and apoptosis. | ||||||
Dolastatin 10 | 110417-88-4 | sc-507413 | 5 mg | $980.00 | ||
Dolastatin 10 is a natural product originally found in sea hare Dolabella auricularia. It inhibits tubulin polymerization and disrupts the microtubule network, leading to cell death. Dolastatin 10 and its derivatives have shown promise in research studies for various cancers. | ||||||